On December 19, 2023, Canton Biologics, an internationally leading biologics CDMSO company, and SinoMab BioScience Limited, a Hong Kong‑based biopharmaceutical company focused on the research, development, manufacturing, and commercialization of therapies for immune diseases, announced in Suzhou the signing of a cooperation agreement for the commercial production of SinoMab’s flagship product, Suciraslimab (SM03). Canton Biologics will leverage its sustained and stable commercial manufacturing capabilities and world‑class GMP quality management system to ensure the optimized supply of Suciraslimab injection after its market launch. The strategic partnership has a total value of up to 600 million yuan.
Mr. Gao Xiaowei
Vice President of Operations, Canton Biologics
“Since its establishment, Canton Biologics has always adhered to the values of ‘Reliable, Efficient, Innovative’ and the mission of ‘Empowering the Future with Biotechnology’ to accelerate the high‑quality R&D and market launch of new drugs. We are very pleased to form a strategic partnership with SinoMab. Canton Biologics will use its strengths to continuously empower clients, helping SinoMab advance Suciraslimab injection into the commercial stage and continue to provide better services to patients in China.”
Dr. Shen Xiao
Founder and CEO, Canton Biologics
“China’s biopharmaceutical industry is still in a cold winter, but SinoMab gives us hope. We see that Chinese technologies are gradually going global. In a highly competitive environment, only truly innovative pharmaceutical companies can reach the world. Canton Biologics is honored to partner with an outstanding company like SinoMab that focuses on innovation and R&D. Canton Biologics is also very willing to support SinoMab in achieving commercial success in China and internationally.”
Mr. Wang Shanchun
China Region President, SinoMab
“As an international, technology‑driven, one‑stop CDMSO company, Canton Biologics has demonstrated a high level of professionalism in the biopharmaceutical field. We highly value Canton Biologics’ outstanding development capabilities, customer‑centric service philosophy, and international manufacturing capabilities. We are delighted to join hands with Canton Biologics. We hope to take this cooperation as an opportunity to jointly explore deeper and more extensive collaboration, working together to provide stable and effective therapeutic drugs for patients with autoimmune diseases in China.”
Dr. Leung Rei On
Chairman, Executive Director, and CEO, SinoMab
“Suciraslimab (SM03), independently developed by SinoMab, is the first CD22 antibody in China and the world’s first anti‑CD22 monoclonal antibody for the treatment of rheumatoid arthritis (RA). It also has potential therapeutic effects on other autoimmune diseases such as systemic lupus erythematosus (SLE), non‑Hodgkin’s lymphoma (NHL), and Sjögren’s syndrome (SS). It employs a novel mechanism of action that differs from existing treatments, overcoming the limitations of conventional therapies in terms of efficacy and safety. Because Suciraslimab targets the unique B‑cell epitope CD22, it effectively addresses the issue of drug resistance that often develops after long‑term use of existing RA therapies targeting mature targets. Based on its mechanism of action and clinical performance, Suciraslimab offers a new option for RA patients to achieve long‑term therapeutic benefits. Clinical studies have confirmed its efficacy in treating autoimmune diseases and controlling inflammation, with excellent long‑term safety and rare serious adverse reactions. It also has the potential to become a novel treatment for Alzheimer’s disease.”
SinoMab has inherited and continued the 20‑year research history of the CD22 target, pioneering its application in the broad field of autoimmune diseases.
About SinoMab
SinoMab BioScience Limited is dedicated to the research, development, manufacturing, and commercialization of therapies for immune diseases. The company focuses on innovative R&D. Based on its globally pioneering “Framework Reengineering” platform and unique “functional humanization” technology, it continuously improves antibody affinity while eliminating the immunogenicity of recombinant antibodies while preserving antibody specificity. Supported by these technologies, the company has developed a rich product pipeline, including but not limited to SM03, SM17, SM06, SM09 at various clinical stages, as well as preclinical candidates such as SM18, SM32, and SM20/SM22.
